Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD

Respiratory Research

Volumn 17, Issue 1, 2016, Pages

  Fabbri, Leonardo M ^a   Kerwin, Edward M ^b   Spangenthal, Selwyn ^c   Ferguson, Gary T ^d   Rodriguez Roisin, Roberto ^e,i   Pearle, James ^f   Sethi, Sanjay ^g   Orevillo, Chad ^h   Darken, Patrick ^h   St Rose, Earl ^h   Fischer, Tracy ^h   Golden, Michael ^h   Dwivedi, Sarvajna ^h   Reisner, Colin ^h  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Clinical Research Institute of Southern Oregon PC   (United States)

^c American Health Research Inc   (United States)

^d Pulmonary Research Institute of Southeast Michigan   (United States)

^e HOSPITAL CLÍNIC   (Spain)

^f California Research Medical Group   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h ASTRAZENECA   (United Kingdom)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Bronchodilators; Co suspension delivery technology; COPD maintenance; LAMA; Metered dose inhaler

Indexed keywords

GLYCOPYRRONIUM; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRY POWDER INHALER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTENSION; INSPIRATORY CAPACITY; INTENTION TO TREAT ANALYSIS; LIMB PAIN; MALE; METERED DOSE INHALER; MULTICENTER STUDY; MUSCLE SPASM; OPEN STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; TREATMENT OUTCOME; VERY ELDERLY; XEROSTOMIA; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; LUNG; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; UNITED STATES; VITAL CAPACITY;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EQUIPMENT DESIGN; FEMALE; FORCED EXPIRATORY VOLUME; GLYCOPYRROLATE; HUMANS; LUNG; MALE; MAXIMUM TOLERATED DOSE; METERED DOSE INHALERS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VITAL CAPACITY;

EID: 84987757834     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-016-0426-4     Document Type: Article

References (27)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Diseases (GOLD) 2016. 2016. [http://www.goldcopd.org]. Accessed 16 June 2016.
2. Lavorini F, Corrigan CJ, Barnes PJ, Dekhuijzen PR, Levy ML, Pedersen S, et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011;105:1099-103.
3. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26:174-9.
4. Prime D, de Backer W, Hamilton M, Cahn A, Preece A, Kelleher D, et al. Effect of disease severity in asthma and chronic obstructive pulmonary disease on inhaler-specific inhalation profiles through the ELLIPTA dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2015;28:486-97.
5. Vehring R, Lechuga-Ballesteros D, Joshi V, Noga B, Dwivedi SK. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28:15015-23.
6. Rennard S, Fogarty C, Reisner C, Fernandez C, Fischer T, Golden M, et al. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2014;14:118.
7. Reisner C, Kerwin EM, Spangenthal S, Fernandez C, Rose ES, Covino J, et al. Pearl Therapeutics' LAMA MDI (GP MDI, PT001) provides a significant benefit in forced expiratory volume in 1 second (FEV1) in doses ranging from 36 μg to 4.6 μg compared to Atrovent HFA, and placebo in a randomized, double-blind, placebo-controlled phase IIb study in patients with COPD. 2013. [http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A4267]. Accessed 21 June 2016.
8. Reisner C, Gotfried M, Denenberg MB, Fernandez C, St Rose E, Fortner P, et al. Low doses of Pearl Therapeutics' LAMA/LABA combination MDI (GFF MDI, PT003) provide superior bronchodilation compared to components and to open-label Spiriva Handihaler in a randomized, double-blind, placebo-controlled Phase IIb study in patients with COPD. 2013. [http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A2434]. Accessed 21 June 2016.
9. Orevillo C, Gotfried M, Denenberg MB, Fernandez C, Darken P, Rose ES, et al. Combination glycopyrronium and formoterol fumarate inhalation aerosol (PT003) at a dose of 14.4/9.6 μg provides superior improvement in inspiratory capacity compared to tiotropium dry powder inhaler (DPI) in subjects with moderate to severe COPD. 2014. [http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A3759]. Accessed 14 June 2016.
10. Reisner C, Ezzet F, Thomas M, Fernandez C, Rose ES, Strom S, et al. Integrated FEV1 and pharmacokinetic relationship of Pearl Therapeutics' formoterol fumarate MDI (FF-MDI, PT005) and Foradil® Aerolizer® from two randomized, placebo-controlled, studies in patients with moderate to severe COPD. 2012. [http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A2928]. Accessed 21 June 2016.
11. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-46.
12. National Center for Health Statistics. Spirometry Procedure Manual. Third National Health and Examination Survey III. 1988.
13. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-38.
14. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. World Medical Association Declaration of Helsinki. 2008.
15. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111-24.
16. Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484-94.
17. Beeh KM, Westerman J, Kirsten AM, Hebert J, Gronke L, Hamilton A, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53-9.
18. Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013;10:511-22.
19. Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falqués M, et al. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest. 2012;141:745-52.
20. Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VK, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40:1106-14.
21. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416-69.
22. Casaburi R, Briggs Jr DD, Donohue JF, Serby CW, Menjoge SS, Witek Jr TJ. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest. 2000;118:1294-302.
23. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1136-42.
24. Price D, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruct Pulmon Dis. 2013;8:595-603.
25. Stephenson JJ, Cai Q, Mocarski M, Tan H, Doshi JA, Sullivan SD. Impact and factors associated with nighttime and early morning symptoms among patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:577-86.
26. Geiger-Brown J, Lindberg S, Krachman S, McEvoy CE, Criner GJ, Connett JE, et al. Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:389-97.
27. Omachi TA, Blanc PD, Claman DM, Chen H, Yelin EH, Julian L, et al. Disturbed sleep among COPD patients is longitudinally associated with mortality and adverse COPD outcomes. Sleep Med. 2012;13:476-83.